Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. | ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S.

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion (OPDP). | Sprout ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...

Havas Media Network has set up an advertising marketplace to help companies reach patients who are cut off from healthcare by ...

With great power comes great responsibility, and Insulet, accordingly, is using its influence in the diabetes management ...

Despite an outcry from the biopharmaceutical industry, the U.K. government has kept the rebate rate under a national ...